KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Profit After Tax (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Profit After Tax for 13 consecutive years, with -$3.8 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 70.03% to -$3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$33.5 million through Dec 2025, up 52.09% year-over-year, with the annual reading at -$33.5 million for FY2025, 52.09% up from the prior year.
  • Profit After Tax hit -$3.8 million in Q4 2025 for Arbutus Biopharma, up from -$7.7 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $2.5 million in Q2 2025 to a low of -$24.5 million in Q1 2025.
  • Historically, Profit After Tax has averaged -$16.1 million across 5 years, with a median of -$17.7 million in 2022.
  • Biggest five-year swings in Profit After Tax: plummeted 37.62% in 2021 and later soared 112.74% in 2025.
  • Year by year, Profit After Tax stood at -$21.3 million in 2021, then decreased by 2.87% to -$21.9 million in 2022, then grew by 11.95% to -$19.3 million in 2023, then soared by 35.11% to -$12.5 million in 2024, then skyrocketed by 70.03% to -$3.8 million in 2025.
  • Business Quant data shows Profit After Tax for ABUS at -$3.8 million in Q4 2025, -$7.7 million in Q3 2025, and $2.5 million in Q2 2025.